Longeveron shares have surged 9.01% following a $30 million private placement deal announced on March 10. The move comes ahead of an expected Q4 earnings print where analysts predict an EPS loss of 38 cents and $106,200, a significant decline from the $603,000 reported the previous year. The deal was structured in two tranches, with the initial $15 million intended to advance the company's lead candidate for rare pediatric conditions. This capital infusion ensures that Longevaron's future funding is secure through the high-profile Phase 2b ELPIS II trial data readout for Hypoplastic Left Heart Syndrome. The stock's Relative Strength Index (RSI) has recently risen above 70.